Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05144347 · ClinicalTrials.gov registry record · Phase 1
Study of XL114 in Subjects With Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by Exelixis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT05144347: Clinical Trial Phase 1 study, sponsored by Exelixis.
NCT05144347 is a Phase 1 study that was terminated before completion, run by Exelixis. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05144347, a Phase 1 study, was terminated before completion, sponsored by Exelixis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a Phase 1, non-randomized, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical antitumor activity of XL114 administered alone orally to subjects with Non-Hodgkin's Lymphoma (NHL). The objectives of the study also include determining the recommended dose (RD) and/or maximum tolerated dose (MTD) of XL114.
Primary Outcome
To determine the RD and/or MTD of XL114 administered orally in subjects with NHL
Interventions
- DRUG XL114
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2022-04-12 |
| Est. Completion | 2022-11-01 |
| Phase | Phase 1 |
Why NCT05144347 stopped before completion
NCT05144347 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which XL114 is the first listed.
NCT05144347 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05144347 about?
NCT05144347 is a clinical study titled "Study of XL114 in Subjects With Non-Hodgkin's Lymphoma". This is a Phase 1, non-randomized, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical antitumor activity of XL114 administered alone orally to subjects with Non-Hodgkin's Lymphoma (NHL). The obj...
What is the current status of trial NCT05144347?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2022-04-12. Estimated completion is 2022-11-01.
What interventions are being tested in trial NCT05144347?
The interventions under investigation include: XL114 (DRUG).
Who is sponsoring clinical trial NCT05144347?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05144347's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI